Tryptamine Therapeutics’ ASX Debut and Clinical Advances
Company Announcements

Tryptamine Therapeutics’ ASX Debut and Clinical Advances

Tryptamine Therapeutics (AU:TYP) has released an update.

Tryptamine Therapeutics, a clinical-stage biotech firm, has successfully listed on the ASX and raised $6.5 million to advance its clinical trials, including a groundbreaking IV-infused psilocin treatment aimed at addressing the limitations of oral psilocybin. The company has appointed industry experts to guide product registration and reimbursement strategies and renewed the term of a leading psychedelics researcher, Dr. Robin Carhart-Harris, as Chair of their Scientific Advisory Board.

For further insights into AU:TYP stock, check out TipRanks’ Stock Analysis page.

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App